Seattle Flow Your front door to Seattle's startup scene.
Sign in
Stream Events Podcasts Videos Communities
Taylor Soper / GeekWire

Eliem Therapeutics raises $60M to advance Phase 2a pain and depression drugs, two months after $80M round

Seattle neurology startup Eliem Therapeutics raised $60 million to advance two Phase 2a drug candidates for chronic pain and depression two months after an $80 million raise; the company is led by CEO Bob Azelby and backed by Intermediate Capital Group and others.

  • Link
  • Report this item
Replying to

No comments yet.

Seattle Flow — Your front door to Seattle's startup scene.

Run by Marcelo Calbucci MC
Send us a link Terms of Service Privacy For AI assistants
© 2026 Seattle Flow. All rights reserved.

Who liked this

Edit history

Seattle Flow

Your front door to Seattle's startup scene.

Seattle's startup scene is scattered across a hundred feeds, newsletters, and calendars. Seattle Flow brings it together: the news, events, podcasts, and people, plus what the community is saying about them. Every link sends you to the source.

Writing about a Seattle founder, fund, or startup? We'll help it get seen. Found a great story we missed? Send it in.

We're in beta and building this with the community. Tell us what you want to see here.

Seattle's startup scene, every day. The news, events, podcasts, and people, plus what everyone's saying about them. We're in beta: send us a story or tell us what you want to see.